Nucleic acid-based vaccine for ovarian cancer cells; bench to bedside

Sulieman Ibraheem Shelash Al-Hawary; Saade Abdalkareem Jasim; Ahmed Hjazi; Enwa Felix Oghenemaro; Irwanjot Kaur; Abhinav Kumar; Ahmed Muzahem Al-Ani; Enas R Alwaily; Ahmed Huseen Redhee; Yasser Fakri Mustafa

doi:10.1002/cbf.3978

Nucleic acid-based vaccine for ovarian cancer cells; bench to bedside

Cell Biochem Funct. 2024 Mar;42(2):e3978. doi: 10.1002/cbf.3978.

Authors

Affiliations

¹ Department of Business Administration, Business School, Al al-Bayt University, Mafraq, Jordan.
² Medical Laboratory Techniques Department, Al-maarif University College, Anbar, Iraq.
³ Biotechnology Department, College of Applied Science, Fallujah University, Fallujah, Iraq.
⁴ Department of Medical Laboratory, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia.
⁵ Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Delta State University, Abraka, Nigeria.
⁶ Department of Biotechnology and Genetics, Jain (Deemed-to-be) University, Bengaluru, Karnataka, India.
⁷ Department of Allied Healthcare and Sciences, Vivekananda Global University, Jaipur, Rajasthan, India.
⁸ Department of Nuclear and Renewable Energy, Ural Federal University Named after The First President of Russia, Yekaterinburg, Russia.
⁹ Department of Medical Engineering, Al-Nisour University College, Baghdad, Iraq.
¹⁰ Microbiology Research Group, College of Pharmacy, Al-Ayen University, Thi-Qar, Iraq.
¹¹ Medical Laboratory Technique College, The Islamic University, Najaf, Iraq.
¹² Medical Laboratory Technique College, The Islamic University of Al Diwaniyah, Al Diwaniyah, Iraq.
¹³ Medical Laboratory Technique College, The Islamic University of Babylon, Babylon, Iraq.
¹⁴ Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul, Iraq.

PMID: 38515237
DOI: 10.1002/cbf.3978

Abstract

Ovarian cancer continues to be a difficult medical issue that affects millions of individuals worldwide. Important platforms for cancer immunotherapy include checkpoint inhibitors, chimeric antigen receptor T cells, bispecific antibodies, cancer vaccines, and other cell-based treatments. To avoid numerous infectious illnesses, conventional vaccinations based on synthetic peptides, recombinant subunit vaccines, and live attenuated and inactivated pathogens are frequently utilized. Vaccine manufacturing processes, however, are not entirely safe and carry a significant danger of contaminating living microorganisms. As a result, the creation of substitute vaccinations is required for both viral and noninfectious illnesses, including cancer. Recently, there has been testing of nucleic acid vaccines, or NAVs, as a cancer therapeutic. Tumor antigens (TAs) are genetically encoded by DNA and mRNA vaccines, which the host uses to trigger immune responses against ovarian cancer cells that exhibit the TAs. Despite being straightforward, safe, and easy to produce, NAVs are not currently thought to be an ideal replacement for peptide vaccines. Some obstacles to this strategy include selecting the appropriate therapeutic agents (TAs), inadequate immunogenicity, and the immunosuppressive characteristic of ovarian cancer. We focus on strategies that have been employed to increase NAVs' effectiveness in the fight against ovarian cancer in this review.

Keywords: cancer vaccine; nucleic acid; ovarian cancer; therapy; tumors.

Publication types

Review

MeSH terms

Antigens, Neoplasm
Cancer Vaccines* / therapeutic use
Female
Humans
Nucleic Acid-Based Vaccines
Ovarian Neoplasms* / drug therapy

Substances

Nucleic Acid-Based Vaccines
Antigens, Neoplasm
Cancer Vaccines